Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28389515 | 0.74 | JAK2 (0.46) | JAK2THRB | |
| SCHEMBL4381730 | 0.74 | ADORA2B (0.34) | — | |
| SCHEMBL6932287 | 0.71 | ALDH1A1 (0.33) | KDM4EGAAHPGDHSD17B10 | |
| SCHEMBL17793999 | 0.68 | PDE4A (0.58) | HPGDHSD17B10 | |
| SCHEMBL11160084 | 0.66 | MAPT (0.53) | TYMPHPGDHSD17B10 | |
| SCHEMBL3788752 | 0.65 | DAO (0.41) | TYMPCSNK2A2CSNK2BCSNK2A1KDM4E | |
| SCHEMBL7544529 | 0.64 | LGMN (0.37) | PTK2KDM4EGAAHPGDHSD17B10 | |
| SCHEMBL1930157 | 0.64 | MCL1 (0.43) | TYMPKDM4EHPGDHSD17B10CRBN | |
| Hydrochloric Acid SCHEMBL9035929 | 0.64 | CHRNB2 (0.40) | TYMPCSNK2A2CSNK2BCSNK2A1KDM4E | |
| SCHEMBL14306615 | 0.63 | LMNA (0.44) | KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010912-A | Antiviral 1, 3-dioxoindene compounds | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4702011-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | Novartis AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-06-12 | — | — | US | disclosed |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2025-04-29 | — | — | US | disclosed |
| WO-2024226581-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2024-10-31 | — | — | WO | disclosed |
| CN-115867545-A | Antiviral 1,3 dioxoindene compounds | 诺华股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4139301-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214080-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | TYMP 162/4885PTK2 4795/4885JAK2 1076/4885 |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | TYMP 162/4885PTK2 4795/4885JAK2 1076/4885 |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, ZC3HAV1 | TYMP 162/4885PTK2 4795/4885JAK2 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.